According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

By addressing these issues, we can ensure that all patients, regardless of their socioeconomic status, have the opportunity ...

Real-world treatment with liso-cel showed a broad spectrum of outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell ...

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

With a link to specific genetic mutations in myelodysplastic syndromes, tobacco smoking may be associated with disease progression and survival.

Rapid Taper Plays Role in Suspected Opioid Misuse in Patients With Cancer ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Rapid Taper Plays Role in Suspected Opioid Misuse in Patients With Cancer ...